SEARCH

SEARCH BY CITATION

References

  • 1
    Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986; 315: 15751578.
  • 2
    Issacs A, Lindenmann J. Virus interference. I. The interferon. Proc Royal Soc London [Biol] 1957; 147: 258267.
  • 3
    Johnson HM, Bazer FW, Szente BE, Jarpe MA. How interferons fight disease. Scientific Am 1994; 68–75.
  • 4
    Gutterman JU. Cytokine therapeutics: Lessons from interferon alfa. Proc Natl Acad Sci 1994; 91: 11981205.
  • 5
    Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112: 10171021.
  • 6
    Carithers RL, Jr., Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26 (suppl 1): 83S88S.
  • 7
    Lee WM. Therapy of hepatitis C: interferon alfa-2a trials. Hepatology 1997; 26 (suppl 1): 89S95S.
  • 8
    Farrell GC. Therapy of hepatitis C: interferon alfa-nl trials. Hepatology 1997; 26 (suppl 1): 96S100S.
  • 9
    Dhib-Jalbut S, Jiang H, Xia Q, Blatt L, Johnson KP, Hilt D. Comparative effects of interferon-consensus 1, interferon-alfa2a, and interferon-β1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis. J Interferon Cytokine Res 1996; 16: 195200.
  • 10
    Keeffe EB, Hollinger FB, and the Consensus Interferon Study Group. Therapy of hepatitis C: consensus interferon trials. Hepatology 1997; 26 (suppl 1): 101S107S.
  • 11
    Gerrard TL, Thorpe R, Jeffcoate S, Reynolds C. Rapid communication: biological potency standards for cytokines and growth factors. Biologicals 1993; 21: 7779.
  • 12
    Mire-Sluis AR, Das RG, Zoon K, Padilla A, Thorpe R, Meager A. The biologic properties, assay, and standardization of interferon-alpha: a need for a WHO collaborative study. J Interferon Cytokine Res 1994; 16: 637643.
  • 13
    Davis GL, Balart LA, Schiff ER, Lindsay KL, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1990; 321: 15011506.
  • 14
    Gretch DR, Rosa CD, Corey L, Carithers RL. Assessment of hepatitis C viremia using molecular amplification technologies. Viral Hepatitis Rev 1996; 2: 8596.
  • 15
    Okada SI, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992; 16: 619624.
  • 16
    Roffi L, Colloredo M, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology and management. Hepatology 1995; 21: 645649.
  • 17
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431435.
  • 18
    Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778789.
  • 19
    Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996; 24: 10341040.
  • 20
    Fattovich G, Giustina G, Favarato S, Ruol A Investigators of the Italian Association for the Study of the Liver. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J HEPATOLOGY 1996; 24: 3847.
  • 21
    Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26 (suppl 1): 112S121S.
  • 22
    Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Pouliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotypes are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 10501056.
  • 23
    Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26 (suppl 1): 122S127S.
  • 24
    Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to alpha interferon therapy in chronic hepatitis C [editorial]. Hepatology 1995; 22: 13261329.
  • 25
    Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 19061911.
  • 26
    Crowe J, Doyle C, Fielding JF, Holloway H, Keegan M, Kelleher D, Kelly P, et al. Presentation of hepatitis C in a unique uniform cohort 17 years from inoculation [Abstract]. Gastroenterology 1995; 108: 1054A.
  • 27
    Yano M, Hiromitsu K, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 13341340.
  • 28
    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; in press.
  • 29
    Marcellin P, Lévy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26 (suppl 1): 133S136S.
  • 30
    Pockros PJ, Tong MJ, Lee WM, van Leeuwen DJ, Keeffe E, Bala K, Killenberg PG, et al. Relationship between biochemical and virological response to type 1 interferon therapy of chronic HCV infection [Abstract]. Hepatology 1996; 24: 155A.
  • 31
    McHutchinson JG, Sedghi-Vazir A, Russell J, Schmid P, Conrad A. Is there an optimal time to measure quantitative HCV RNA to predict outcome following interferon treatment for chronic HCV infection [Abstract]? Hepatology 1996; 24: 356A.
  • 32
    Colloredo G, Bellati G, Ricci A, Scalori A, Redaelli A, Bellobuono A, Bissoli F, et al. HCV-RNA as a predictor of relapse after interferon therapy for chronic hepatitis C [Abstract]. Hepatology 1996; 24: 156A.
  • 33
    Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 1997; 26 (suppl 1): 137S142S.
  • 34
    Boyer N, Marcellin P, Duchatelle V, Martinet M, Kilani A, Pouteau M, Descombes I, et al. Sustained response after alpha interferon therapy in patients with chronic hepatitis C [Abstract]. Hepatology 1995; 22: 291 A.
  • 35
    Balistreri WF. Treatment of chronic hepatitis C in children. Viral Hepatitis Rev 1995; 1: 121128.
  • 36
    Araya V, Rakela J, Wright T. Hepatitis C after orthotopic liver transplantation. Gastroenterology 1997; 112: 575582.
  • 37
    Rosen HR, Friedman LS, Martin P. Hepatitis C in renal dialysis and transplant patients. Viral Hepatitis Rev 1996; 2: 97110.
  • 38
    Garcia G, Terrault N, Wright TL. Hepatitis C virus infection in the immunocompromised patient. Semin Gastrointest Dis 1995; 6: 3545.
  • 39
    Willson RA. Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 1997; 92: 417.
  • 40
    Schapiro GD, Friedman LS. Autoimmune hepatitis and/or hepatitis C: how to decide. Hepatology 1996; 23: 647649.
  • 41
    Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med 1995; 123: 3234.
  • 42
    Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997; 26 (suppl 1): 128S132S.
  • 43
    Bonkovsky HL. Therapy of hepatitis C: other options. Hepatology 1997; 26 (suppl 1): 143S151S.
  • 44
    Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: ribavirin treatment alone or in combination with interferon. Hepatology 1997; 26 (suppl 1): 108S111S.